Compare Emerson Electric Co. (EMR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Sanofi SA — how do they compare? Emerson Electric Co. trades at $161.17 (market cap $88.72B), while Sanofi SA trades at $40.16 (market cap $95.18B). The key difference: Emerson Electric Co. and Sanofi SA are close in size by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Emerson Electric Co. for 81 Days and Sanofi SA for 94 Days on average.
| EMR | SNY | |
|---|---|---|
Market Cap | $88.72B | $95.18B |
Volume | 2,355,255 | 2,995,646 |
Sector | Industrials | Health |
52-Week High | $164.38 | $52.34 |
52-Week Low | $123.30 | $39.51 |
Typical Hold Time | 81 Days | 94 Days |
Enterprise Value | $99.80B | $114.48B |
Dividend Yield | 1.4% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $161.13, up 1.2% today, with a bullish technical trend and strong quarterly earnings beats. The stock is supported by a 53.49% analyst buy consensus and a $165.90 price target. Revenue growth is steady, with 2025 revenue at $18.02B and net income of $2.29B, while profitability metrics like a 13.83% net margin and 12.81% ROE reflect operational strength. Recent news highlights momentum and Wall Street optimism, though valuation multiples like a P/E of 34.81 suggest premium pricing.
EMR's outlook is positive, driven by earnings momentum and analyst confidence, but risks include elevated valuation and debt levels. The stock offers growth potential with a dividend, yet investors face headwinds from competitive pressures and economic cycles. Upside to the consensus target implies modest gains, balancing fundamental strength with valuation concerns.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
